AP
HAE icon

AHL Partners’s Haemonetics HAE Stock Holding History

AHL Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$2.1M Sell
36,246
-72,730
-67% -$3.83M 0.03% 708
2017
Q3 		$4.89M Sell
108,976
-67,743
-38% -$2.81M 0.09% 411
2017
Q2 		$6.98M Buy
176,719
+31,401
+22% +$1.29M 0.15% 231
2017
Q1 		$5.89M Buy
145,318
+131,918
+984% +$5.15M 0.13% 282
2016
Q4 		$538K Sell
13,400
-2,019
-13% -$76.1K 0.02% 809
2016
Q3 		$558K Sell
15,419
-36,434
-70% -$1.25M 0.02% 800
2016
Q2 		$1.5M Buy
51,853
+44,597
+615% +$1.35M 0.08% 314
2016
Q1 		$254K Sell
7,256
-23,604
-76% -$762K 0.02% 697
2015
Q4 		$995K Buy
30,860
+18,113
+142% +$588K 0.08% 364
2015
Q3 		$412K Buy
12,747
+3,371
+36% +$127K 0.07% 446
2015
Q2 		$388K Buy
9,376
+3,049
+48% +$129K 0.02% 737
2015
Q1 		$284K Buy
6,327
+731
+13% +$30.6K 0.01% 721
2014
Q4 		$209K Sell
5,596
-1,592
-22% -$58.3K 0.01% 722
2014
Q3 		$251K Buy
+7,188
New +$256K 0.02% 640

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AHL Partners's HAE Position: Q4 2017 in Review

AHL Partners reduced its Haemonetics (HAE) stake by 67% in Q4 2017, selling an estimated $3.83M and leaving 36,246 shares worth $2.1M. The position accounts for 0.03% of the portfolio, ranked #708.

AHL Partners first reported a position in HAE in Q3 2014 and has held it in 14 quarters since. The position peaked at $6.98M in Q2 2017. 246 funds tracked by Wall St. Rank hold HAE as of Q4 2017.

  • AHL Partners held 36,246 shares of Haemonetics worth $2.1M as of Q4 2017.
  • AHL Partners sold 72,730 Haemonetics shares in Q4 2017, an estimated $3.83M.
  • Haemonetics made up 0.03% of AHL Partners's portfolio in Q4 2017, its #708 holding.
  • AHL Partners first reported a position in Haemonetics in Q3 2014 and has held it in 14 quarters since.
  • AHL Partners's Haemonetics position peaked at $6.98M in Q2 2017.
  • 246 funds tracked by Wall St. Rank held Haemonetics as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.